Triparanol: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A cholesterol-lowering drug | {{Short description|A synthetic cholesterol-lowering drug}} | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 477002123 | ||
| image = Triparanol.svg | | image = Triparanol.svg | ||
| | | image2 = | ||
}} | }} | ||
'''Triparanol''' was a cholesterol-lowering drug that was | '''Triparanol''' was a cholesterol-lowering drug that was developed in the 1950s and marketed in the early 1960s. It was withdrawn from the market due to adverse effects. | ||
==History== | ==History== | ||
Triparanol was | Triparanol was introduced as a cholesterol-lowering agent in the early 1960s. It was marketed under the brand name MER/29. The drug was one of the first synthetic agents used to lower cholesterol levels in the blood. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Triparanol works by inhibiting the enzyme [[desmosterol]] _24-reductase, which is involved in the biosynthesis of [[cholesterol]]. | Triparanol works by inhibiting the enzyme [[desmosterol]] _24-reductase, which is involved in the biosynthesis of [[cholesterol]]. This inhibition leads to the accumulation of desmosterol, a precursor in the cholesterol synthesis pathway, and a reduction in cholesterol levels. | ||
==Adverse Effects== | ==Adverse Effects== | ||
Despite its | Despite its effectiveness in lowering cholesterol, Triparanol was associated with several adverse effects. Patients reported side effects such as cataracts, alopecia, and skin disorders. These adverse effects were significant enough to lead to the withdrawal of the drug from the market. | ||
==Withdrawal== | ==Withdrawal from the Market== | ||
Due to the severe side effects, | Due to the severe side effects, Triparanol was withdrawn from the market in 1962. The withdrawal highlighted the importance of thorough drug testing and monitoring for adverse effects. | ||
==Legacy== | ==Legacy== | ||
The case of | The case of Triparanol is often cited in discussions about drug safety and the importance of post-marketing surveillance. It serves as a reminder of the potential risks associated with new pharmaceuticals and the need for rigorous clinical trials. | ||
==Related pages== | ==Related pages== | ||
* [[Cholesterol]] | * [[Cholesterol]] | ||
* [[Desmosterol]] | * [[Desmosterol]] | ||
* [[ | * [[Drug safety]] | ||
[[Category:Cholesterol-lowering drugs]] | |||
[[Category:Withdrawn drugs]] | [[Category:Withdrawn drugs]] | ||
Revision as of 03:50, 13 February 2025
A synthetic cholesterol-lowering drug
| Triparanol | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Triparanol was a cholesterol-lowering drug that was developed in the 1950s and marketed in the early 1960s. It was withdrawn from the market due to adverse effects.
History
Triparanol was introduced as a cholesterol-lowering agent in the early 1960s. It was marketed under the brand name MER/29. The drug was one of the first synthetic agents used to lower cholesterol levels in the blood.
Mechanism of Action
Triparanol works by inhibiting the enzyme desmosterol _24-reductase, which is involved in the biosynthesis of cholesterol. This inhibition leads to the accumulation of desmosterol, a precursor in the cholesterol synthesis pathway, and a reduction in cholesterol levels.
Adverse Effects
Despite its effectiveness in lowering cholesterol, Triparanol was associated with several adverse effects. Patients reported side effects such as cataracts, alopecia, and skin disorders. These adverse effects were significant enough to lead to the withdrawal of the drug from the market.
Withdrawal from the Market
Due to the severe side effects, Triparanol was withdrawn from the market in 1962. The withdrawal highlighted the importance of thorough drug testing and monitoring for adverse effects.
Legacy
The case of Triparanol is often cited in discussions about drug safety and the importance of post-marketing surveillance. It serves as a reminder of the potential risks associated with new pharmaceuticals and the need for rigorous clinical trials.
